Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT) Mechelen, Belgium; 4 April 2024, 22:01 CET – Galapagos NV ((Euronext &amp, NASDAQ:GLPG) today announced that four abstracts, including two oral presentations on encore preliminary clinical and translational data for its seven-day vein-to-vein CAR-T product candidates GLPG5101 and GLPG5201, will be presented at th ...